Palvella Therapeutics Inc. (PVLA) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Palvella Therapeutics Inc. (PVLA) surged +2.79% to $151.58, trading at 89% of its 52-week range ($71.55 – $161.38). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.
WAYNE, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies f
QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting an estimated more than 30,000 diagnosed children and adults in the U.S. Ph
Palvella Therapeutics (NASDAQ:PVLA) is preparing for a potential commercial launch of QTORIN rapamycin while advancing additional rare skin and vascular anomaly programs, Chief Financial Officer Matt Korenberg said durin
Palvella Therapeutics (NasdaqGM:PVLA) reported positive Phase 3 SELVA trial results for QTORIN rapamycin in microcystic lymphatic malformations. The company has completed an FDA New Drug Application for QTORIN rapamycin
JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00 p.m.
CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm’s continued expansion of its biotech offering.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PVLA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PVLA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Palvella Therapeutics Inc. (PVLA) ranks #440 by composite RQD confidence (46/100, grade D) and #247 by equity capitalization ($2.18B). Within this direct 5-issuer industry benchmark cohort, PVLA leads on earnings valuation at N/A trailing P/E, while PRGO leads on capital efficiency and profitability with -13.6% ROIC and 35.1% gross margin. PVLA currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PVLA
ACTIVE
Palvella Therapeutics Inc. | D | 46/100 | — | — | -27.9% | +2.79% | $2.18B | Benchmark Subject |
| XNCR Xencor Inc. | D- | 43/100 | — | — | -21.3% | -2.60% | $2.17B | /xncr-vs-pvla → |
| MRVI Maravai LifeSciences Holdings Inc. (Class A) | D- | 36/100 | — | 18.3% | -35.0% | -0.47% | $2.20B | /mrvi-vs-pvla → |
| VERA Vera Therapeutics Inc. (Class A) | D- | 35/100 | — | — | -35.0% | -1.32% | $2.20B | /vera-vs-pvla → |
| PRGO Perrigo Company plc | D- | 41/100 | — | 35.1% | -13.6% | -0.13% | $2.21B | /prgo-vs-pvla → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Palvella Therapeutics Inc. (PVLA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$41.7M, operating cash flow of -$25.0M, and free cash flow of -$25.0M (-130.7% YoY). On the balance sheet, PVLA closed FY2025 with $59.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$41.7M | -$25.0M | -$25.0M | $59.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$17.4M | -$10.8M | -$10.8M | $88.2M | — |
| FY2023 (FY) | 2023-12-31 | $42.8M | $18.7M | -$13.7M | -$13.7M | — | — |
As of 2026-11-01, Palvella Therapeutics Inc. (NASDAQ: PVLA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $151.58 (+2.79% 1D, market cap $2.18B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PVLA ranks #440 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PVLA carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -27.9%. By comparison, XNCR (Xencor Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -21.3%, cap $2.17B) and MRVI (Maravai LifeSciences Holdings Inc. (Class A)) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.20B). Among the 5-stock peer group, PVLA leads on earnings multiple (N/A) while PRGO leads on capital efficiency (-13.6% ROIC).
Per PVLA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001583648), Palvella Therapeutics Inc. generated $0 in revenue, -$41.7M in net income, and -$25.0M in free cash flow against $59.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PVLA last traded at $151.58 (+2.79% on volume of 342,995 shares), positioning the stock +7.15% above its 50-day simple moving average ($141.47) and +19.42% above its 200-day simple moving average ($126.93). Across its 52-week range of $71.55 to $161.38, PVLA sits at the 89.1% percentile with a 14-day RSI of 59.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.2% ($133.09 to $170.07).
Why PVLA Stock surged +2.79% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.